DKN-01 DeFianCe Data Update

company presentation LEAP THERAPEUTICS Sirexatamab (DKN-01) Clinical Development DeFianCe Study Preliminary Results March 26, 2025 Forward looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical trials, collaborations and partnerships, future financial position, future revenues, p ...